103 related articles for article (PubMed ID: 12727936)
21. Serum thyrotropin (TSH) levels after recombinant human TSH injections in children and teenagers with papillary thyroid cancer.
Iorcansky S; Herzovich V; Qualey RR; Tuttle RM
J Clin Endocrinol Metab; 2005 Dec; 90(12):6553-5. PubMed ID: 16174712
[TBL] [Abstract][Full Text] [Related]
22. Epithelial cell thyroid cancer and thyroid stimulating hormone--when less is more.
Emerson CH; Colzani R; Braverman LE
J Clin Endocrinol Metab; 1997 Jan; 82(1):9-10. PubMed ID: 8989222
[No Abstract] [Full Text] [Related]
23. Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma.
Luster M; Lassmann M; Haenscheid H; Michalowski U; Incerti C; Reiners C
J Clin Endocrinol Metab; 2000 Oct; 85(10):3640-5. PubMed ID: 11061516
[TBL] [Abstract][Full Text] [Related]
24. [Thyroid dysfunction in the aged].
Marañón Cabello A
An Med Interna; 2000 Jan; 17(1):1-4. PubMed ID: 10730396
[No Abstract] [Full Text] [Related]
25. The continuous debate in literature about the usage of iodine-131 dosing for the ablation of thyroid remnants and metastases.
De Klerk JM; Oyen WJ
Minerva Endocrinol; 2009 Mar; 34(1):57-69. PubMed ID: 19209128
[TBL] [Abstract][Full Text] [Related]
26. Commentary on article by Rudavsky and Freeman.
Lukinac L; Franceschi D; Kusic Z
J Clin Endocrinol Metab; 1997 Dec; 82(12):4277. PubMed ID: 9398757
[No Abstract] [Full Text] [Related]
27. Recombinant human TSH as an adjuvant to radioiodine for the treatment of type 1 amiodarone-induced thyrotoxicosis: a cautionary note.
Bogazzi F; Tomisti L; Ceccarelli C; Martino E
Clin Endocrinol (Oxf); 2010 Jan; 72(1):133-4. PubMed ID: 19508595
[No Abstract] [Full Text] [Related]
28. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal.
Tuttle RM; Brokhin M; Omry G; Martorella AJ; Larson SM; Grewal RK; Fleisher M; Robbins RJ
J Nucl Med; 2008 May; 49(5):764-70. PubMed ID: 18413378
[TBL] [Abstract][Full Text] [Related]
29. The HiLo trial: a multicentre randomised trial of high- versus low-dose radioiodine, with or without recombinant human thyroid stimulating hormone, for remnant ablation after surgery for differentiated thyroid cancer.
Mallick U; Harmer C; Hackshaw A
Clin Oncol (R Coll Radiol); 2008 Jun; 20(5):325-6. PubMed ID: 18474322
[No Abstract] [Full Text] [Related]
30. Radioiodine treatment of well-differentiated thyroid cancer.
Wartofsky L; Van Nostrand D
Endocrine; 2012 Dec; 42(3):506-13. PubMed ID: 22733393
[No Abstract] [Full Text] [Related]
31. Recombinant human TSH associated with radioiodine does not have further effects on thyroid volume and function after 2 years.
Paz-Filho GJ; Mesa CO; Carvalho GA; Goedert CA; Graf H
Clin Endocrinol (Oxf); 2008 Aug; 69(2):345-6. PubMed ID: 18167135
[No Abstract] [Full Text] [Related]
32. Radioiodine treatment for benign thyroid diseases.
Weetman AP
Clin Endocrinol (Oxf); 2007 Jun; 66(6):757-64. PubMed ID: 17466000
[TBL] [Abstract][Full Text] [Related]
33. Treatment of thyroid cancer.
Blahd WH
Compr Ther; 1985 Sep; 11(9):26-32. PubMed ID: 4042593
[No Abstract] [Full Text] [Related]
34. Iodine biokinetics and radioiodine exposure after recombinant human thyrotropin-assisted remnant ablation in comparison with thyroid hormone withdrawal.
Taïeb D; Sebag F; Farman-Ara B; Portal T; Baumstarck-Barrau K; Fortanier C; Bourrelly M; Mancini J; De Micco C; Auquier P; Conte-Devolx B; Henry JF; Mundler O
J Clin Endocrinol Metab; 2010 Jul; 95(7):3283-90. PubMed ID: 20392868
[TBL] [Abstract][Full Text] [Related]
35. A pragmatic protocol for I-131 rhTSH-stimulated ablation therapy in patients with renal failure.
Driedger AA; Quirk S; McDonald TJ; Ledger S; Gray D; Wall W; Yoo J
Clin Nucl Med; 2006 Aug; 31(8):454-7. PubMed ID: 16855429
[TBL] [Abstract][Full Text] [Related]
36. Recombinant human thyroid-stimulating hormone (rhTSH) in the radioablation of well-differentiated thyroid cancer: preliminary therapeutic experience.
Perros P
J Endocrinol Invest; 1999; 22(11 Suppl):30-4. PubMed ID: 10727003
[TBL] [Abstract][Full Text] [Related]
37. Expanding indications for recombinant human TSH in thyroid cancer.
Haugen BR; Cooper DS; Emerson CH; Luster M; Maciel RM; Biscolla RP; Mazzaferri EL; Medeiros-Neto G; Reiners C; Robbins RJ; Robinson BG; Schlumberger M; Yamashita S; Pacini F
Thyroid; 2008 Jul; 18(7):687-94. PubMed ID: 18630995
[No Abstract] [Full Text] [Related]
38. Update on recent developments in the therapy of differentiated thyroid cancer.
Middendorp M; Grünwald F
Semin Nucl Med; 2010 Mar; 40(2):145-52. PubMed ID: 20113682
[TBL] [Abstract][Full Text] [Related]
39. The widened use of exogenous stimulation with recombinant human TSH to treat metastatic thyroid carcinoma in Italy.
Maffioli L; Florimonte L; Fugazzola L; Banti E; Bagnasco M; Dottorini ME; Perotti G; Rubello D; Seregni E; Bombardieri E; Testori O
Q J Nucl Med Mol Imaging; 2012 Oct; 56(5):476-84. PubMed ID: 23069926
[TBL] [Abstract][Full Text] [Related]
40. Thyrotropin in the development and management of differentiated thyroid cancer.
McLeod DS
Endocrinol Metab Clin North Am; 2014 Jun; 43(2):367-83. PubMed ID: 24891167
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
